Trial Profile
An Open Label, Randomized, 3-Period Crossover Study to Evaluate the Comparative Bioavailability of Variably Aged MK-0974 Capsules Administered Orally as Single Doses in Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Telcagepant (Primary)
- Indications Endocrine disorders; Migraine
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 28 Sep 2010 New trial record